Cravath, Swaine & Moore LLP Logo
  • Practices
  • People
  • Careers
  • News & Insights
  • Practices
  • People
  • Careers
  • News & Insights
  • Our Story
  • The Cravath System
  • Diversity & Inclusion
  • Pro Bono
  • Alumni Journal
  • 200.Cravath

Cravath Publishes Summer 2026 Issue of Alumni Journal

Read More

News & Insights

BlackRock’s Senior Secured Revolving Credit Facility

March 02, 2016

Cravath represented the administrative agent, Citibank, N.A., in connection with the arrangement of an increased and extended $440 million senior secured revolving credit facility made available to BlackRock Capital Investment Corporation. The transaction closed on February 19, 2016.

The Cravath team included partner Michael S. Goldman and associates Raffael M. Fiumara, Melody Koh and Sean M. Linnehan on banking matters; partner Andrew W. Needham and associates Dmitry Zelik and Damien J. Rose on tax matters; and associate Peretz Riesenberg on executive compensation and benefits matters.

Related Practices & Industries

  • Corporate
  • Banking and Credit
  • Tax
  • Executive Compensation and Benefits
  • Financial Services and Insurance

People

Photo
Name
Michael S. Goldman
Title
Corporate
Title
Retired Partner
Email
mgoldman@cravath.com
Phone
+1-212-474-1999
vCard
Download vCard

    Education

    • J.D., 1987, Fordham University School of Law
      cum laude
    • B.A., 1984, University of Pennsylvania
      cum laude
    Photo
    Name
    Andrew W. Needham
    Title
    Tax
    Title
    Retired Partner
    Email
    aneedham@cravath.com
    Phone
    +1-212-474-1999
    vCard
    Download vCard

      Education

      • M.B.A., 1992, The Wharton School of the University of Pennsylvania
      • LL.M., 1990, Georgetown University Law Center
      • J.D., 1986, Georgetown University Law Center
      • B.A., 1982, University of Arizona College of Law

      Related News & Insights

      Deals & Cases

      July 06, 2026

      UVEX’s Upsize and Repricing of its Term Loan Facility

      Cravath represented the agent, mandated lead arrangers, and lenders in connection with the repricing of UVEX GROUP GmbH’s €400 million term loan facility and €50 million term loan add-on. UVEX GROUP GmbH is a portfolio company of Warburg Pincus. The transaction closed on June 19, 2026. 

      Deals & Cases

      April 06, 2026

      Versigent’s $1.35 Billion Credit Facilities and $1.6 Billion High‑Yield Senior Notes Offering in Connection with Aptiv PLC’s Spin‑Off of Versigent

      Cravath represented the administrative agent, joint lead arrangers and joint bookrunners in connection with $1.35 billion of credit facilities made available to subsidiaries of Versigent Limited, a global leader in the design, development and manufacture of low voltage and high voltage electrical architectures and the holding company for Aptiv PLC’s Electrical Distribution Systems segment, which Aptiv PLC spun off into a separate, independent, publicly traded company. The proceeds were used to partially finance the spin‑off. The credit facilities consisted of a $500 million term loan facility and an $850 million revolving credit facility. The transaction closed on November 26, 2025.

      Deals & Cases

      February 20, 2026

      First Solar’s $1.5 Billion Revolving Credit Facility

      Cravath represented First Solar, Inc. in connection with its $1.5 billion revolving credit facility. First Solar is America’s leading photovoltaic solar technology and manufacturing company, and the only US‑headquartered company among the world’s largest solar manufacturers. The transaction closed on February 13, 2026.

      Deals & Cases

      January 08, 2026

      Genmab’s $3.5 Billion of Credit Facilities and Offering of $1.5 Billion Senior Secured Notes and $1 Billion Senior Unsecured Notes in Connection with its Acquisition of Merus

      Cravath represented the administrative agent, joint lead arrangers and joint bookrunners in connection with $3.5 billion of credit facilities made available to Genmab, a leading international biotechnology company, and one of its wholly‑owned subsidiaries, Genmab Finance LLC, as part of the financing transactions undertaken in connection with its acquisition of Merus N.V., a leading oncology company developing innovative antibody therapeutics. The credit facilities consisted of a $2 billion term loan “B” facility, a $1 billion term loan “A” facility and a $500 million revolving credit facility. The transaction closed on December 12, 2025.

      Cravath Bicentennial

      Celebrating 200 years of partnership. In 2019, we celebrated our bicentennial. Our history mirrors that of our nation. Integral to our story is our culture.

      Explore

      Cravath, Swaine & Moore LLP Logo
      • CONTACT US
      • OUR STORY
      • ALUMNI PORTAL
      • DISCLAIMERS & NOTICES

      Attorney Advertising. ©2026 Cravath, Swaine & Moore LLP.